Fritz Jänicke

发表

A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.

F. Jänicke, M. Schmitt, W. Kuhn, 1993, The Journal of clinical investigation.

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer

K. Milde-Langosch, R. Wirtz, F. Jänicke, 2010, British Journal of Cancer.

Tumor-associated urokinase-type plasminogen activator: biological and clinical significance.

F. Jänicke, M. Schmitt, H. Graeff, 1992, Biological chemistry Hoppe-Seyler.

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer.

A. Howell, J. Forbes, R. Blamey, 1995, European journal of cancer.

Long-Term Follow-Up Confirms Prognostic Impact of Pai-1 and Cathepsin D and L in Primary Breast Cancer

A. Krüger, N. Harbeck, F. Jänicke, 2000, The International journal of biological markers.

Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.

F. Jänicke, U. Weidle, M. Schmitt, 1995, Journal of obstetrics and gynaecology.

Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.

P. Dettmar, F. Jänicke, M. Schmitt, 1994, Gynecologic oncology.

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.

Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer.

N. Harbeck, P. Dettmar, C. Thomssen, 1997, British Journal of Cancer.

c-FOS suppresses ovarian cancer progression by changing adhesion

U Schumacher, U. Schumacher, A. Tonevitsky, 2013, British Journal of Cancer.

Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.

H. Höfler, P. Dettmar, F. Jänicke, 1995, Cancer research.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

D. Wallwiener, R. Kreienberg, M. Kiechle, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc

H. Höfler, N. Harbeck, P. Dettmar, 1999, British Journal of Cancer.